Pericarditis

Patients with cancer who received immune checkpoint inhibitors rarely developed cardiovascular adverse events, according to results of a systematic review and meta-analysis.

COVID-19 vaccination decreased the risk for CV events, hospitalization and death among patients with HF, according to a poster presented at the European Society of Cardiology’s Heart Failure 2024 meeting.

Acute and recurrent pericarditis are the most common pericardial syndromes and represent an etiology of chest pain that is associated with substantial morbidity, decreased quality of life and, rarely, mortality.

Incidence of myocarditis/pericarditis among veterans was low across more than 10 million doses of messenger RNA COVID-19 vaccines, given as a primary or booster dose, administered at the Veterans Health Administration, researchers found.

Compared with uninfected controls, patients hospitalized for COVID-19 had elevated risk for death and CV events, according to new data from the UK Biobank.

Early data from a phase 2/3 trial suggest that the new Pfizer and BioNTech omicron booster increases protective antibodies against the BA.5 subvariant in adults 7 days after administration.

Myocarditis and pericarditis after COVID-19 vaccination is rare across demographic groups and most likely to occur in teen boys in the week after their second shot of a two-dose vaccine, according to a study.

Advances in imaging techniques and new treatments are changing the management of recurrent pericarditis, improving outcomes for patients with formerly treatment-resistant disease, researchers reported.

An analysis of nationwide data across four Nordic countries shows risk for myocarditis is rare but is highest among young males after a second COVID-19 vaccine dose.

Despite low absolute rates, researchers observed elevated odds of cardiac injury among male adolescents and young adults after messenger RNA-based COVID-19 vaccination in a large U.S. study, as well as a smaller study in Hong Kong.